{"id":"v503","safety":{"commonSideEffects":[{"rate":"70-80%","effect":"Injection site pain"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"V503 works by introducing antigens from multiple HPV types, stimulating the immune system to produce antibodies that can neutralize these viruses before they cause infection and potentially lead to cervical cancer or other HPV-related diseases.","oneSentence":"V503 is a vaccine designed to prevent human papillomavirus (HPV) infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:02.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58"}]},"trialDetails":[{"nctId":"NCT06688058","phase":"PHASE1","title":"A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Healthy","enrollment":72},{"nctId":"NCT07224477","phase":"PHASE2","title":"A Clinical Study of V540A in Healthy Female Participants (V540A-005)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-07-20","conditions":"Healthy","enrollment":525},{"nctId":"NCT05119855","phase":"PHASE3","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-28","conditions":"Papillomavirus Infections, Coronavirus Disease (COVID-19)","enrollment":165},{"nctId":"NCT04635423","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-11-30","conditions":"Warts, Genital, Neoplasms, Anal","enrollment":1059},{"nctId":"NCT06623409","phase":"PHASE1","title":"Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-12","conditions":"Healthy","enrollment":72},{"nctId":"NCT04772534","phase":"PHASE3","title":"Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-17","conditions":"Papillomavirus Infections","enrollment":314},{"nctId":"NCT04199689","phase":"PHASE3","title":"Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-27","conditions":"Papillomavirus Infections","enrollment":6033},{"nctId":"NCT03903562","phase":"PHASE3","title":"Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-27","conditions":"Papillomavirus Infections","enrollment":1990},{"nctId":"NCT05285826","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-02-18","conditions":"Papillomavirus Infections","enrollment":8100},{"nctId":"NCT02653118","phase":"","title":"Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-22","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":4453},{"nctId":"NCT05314023","phase":"PHASE3","title":"Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-07","conditions":"Genital Warts","enrollment":1590},{"nctId":"NCT03998254","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-26","conditions":"Papillomavirus Infections","enrollment":6000},{"nctId":"NCT00943722","phase":"PHASE3","title":"A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-27","conditions":"Cervical Cancers, Vulvar Cancer, Vaginal Cancer","enrollment":3074},{"nctId":"NCT05450705","phase":"PHASE3","title":"V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-22","conditions":"Papillomavirus Infections","enrollment":1500},{"nctId":"NCT03546842","phase":"PHASE3","title":"Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-29","conditions":"Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms","enrollment":201},{"nctId":"NCT03158220","phase":"PHASE3","title":"Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-09-20","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":1212},{"nctId":"NCT01304498","phase":"PHASE3","title":"Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-23","conditions":"Human Papillomavirus","enrollment":600},{"nctId":"NCT00988884","phase":"PHASE3","title":"A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-21","conditions":"Human Papillomavirus Infection","enrollment":1241},{"nctId":"NCT01254643","phase":"PHASE3","title":"A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-12","conditions":"Papillomavirus Infections","enrollment":100},{"nctId":"NCT01651949","phase":"PHASE3","title":"Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-29","conditions":"Genital Warts, Anal Cancer, Anal Intraepithelial Neoplasia","enrollment":2520},{"nctId":"NCT01073293","phase":"PHASE3","title":"A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04-22","conditions":"Papillomavirus Infections","enrollment":1054},{"nctId":"NCT01047345","phase":"PHASE3","title":"A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Cervical Cancers, Vulvar Cancers, Vaginal Cancers","enrollment":924},{"nctId":"NCT00543543","phase":"PHASE3","title":"Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-24","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":14840},{"nctId":"NCT02114385","phase":"PHASE3","title":"A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-24","conditions":"Papilloma Viral Infection","enrollment":500},{"nctId":"NCT01984697","phase":"PHASE3","title":"A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-12","conditions":"Human Papillomavirus Infection","enrollment":1518}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GARDASIL®9 (HPV 9-valent vaccine [recombinant, adsorbed]); HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58","9vHPV vaccine","SILGARD®9","GARDASIL™9"],"phase":"phase_3","status":"active","brandName":"V503","genericName":"V503","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"V503 is a vaccine designed to prevent human papillomavirus (HPV) infection. Used for Prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":11,"withResults":9},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}